ANI Pharmaceuticals Company Profile (NASDAQ:ANIP)

About ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals logoANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $534.95 million
  • Outstanding Shares: 11,637,000
Average Prices:
  • 50 Day Moving Avg: $50.01
  • 200 Day Moving Avg: $55.18
  • 52 Week Range: $43.71 - $70.92
  • Trailing P/E Ratio: 143.66
  • Foreward P/E Ratio: 9.97
  • P/E Growth: 0.93
Sales & Book Value:
  • Annual Revenue: $144.7 million
  • Price / Sales: 3.70
  • Book Value: $14.80 per share
  • Price / Book: 3.11
  • EBIDTA: $58.86 million
  • Net Margins: 7.28%
  • Return on Equity: 21.84%
  • Return on Assets: 11.84%
  • Debt-to-Equity Ratio: 0.70%
  • Current Ratio: 3.13%
  • Quick Ratio: 2.20%
  • Average Volume: 170,713 shs.
  • Beta: 3
  • Short Ratio: 3.58

Frequently Asked Questions for ANI Pharmaceuticals (NASDAQ:ANIP)

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals Inc (NASDAQ:ANIP) issued its quarterly earnings results on Thursday, May, 4th. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.70 by $0.04. The business had revenue of $36.60 million for the quarter, compared to analysts' expectations of $39.63 million. ANI Pharmaceuticals had a net margin of 7.28% and a return on equity of 21.84%. The company's quarterly revenue was up 77.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.76 earnings per share. View ANI Pharmaceuticals' Earnings History.

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals issued an update on its FY17 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of $3.58-$3.94 for the period, compared to the Thomson Reuters consensus estimate of $3.94. The company issued revenue guidance of $181-$190 million, compared to the consensus revenue estimate of $186.95 million.

Where is ANI Pharmaceuticals' stock going? Where will ANI Pharmaceuticals' stock price be in 2017?

5 brokers have issued 12-month price targets for ANI Pharmaceuticals' shares. Their forecasts range from $56.00 to $80.00. On average, they expect ANI Pharmaceuticals' stock price to reach $68.00 in the next twelve months. View Analyst Ratings for ANI Pharmaceuticals.

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a increase in short interest in April. As of April 13th, there was short interest totalling 1,053,912 shares, an increase of 10.0% from the March 31st total of 957,794 shares. Based on an average daily volume of 130,729 shares, the days-to-cover ratio is currently 8.1 days.

Who are some of ANI Pharmaceuticals' key competitors?

Who owns ANI Pharmaceuticals stock?

ANI Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (0.00%), Glenmede Trust Co. NA (3.27%), State Street Corp (2.61%), Renaissance Technologies LLC (0.00%), Nomura Holdings Inc. (1.80%) and Bank of America Corp DE (1.69%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, James G Marken and Robert W Schrepfer. View Institutional Ownership Trends for ANI Pharmaceuticals.

Who sold ANI Pharmaceuticals stock? Who is selling ANI Pharmaceuticals stock?

ANI Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Morgan Stanley, JPMorgan Chase & Co., State Street Corp, Wells Fargo & Company MN, Nisa Investment Advisors LLC, Goldman Sachs Group Inc. and PNC Financial Services Group Inc.. Company insiders that have sold ANI Pharmaceuticals stock in the last year include Arthur Przybyl and Robert W Schrepfer. View Insider Buying and Selling for ANI Pharmaceuticals.

Who bought ANI Pharmaceuticals stock? Who is buying ANI Pharmaceuticals stock?

ANI Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Kennedy Capital Management Inc., Renaissance Technologies LLC, Bank of America Corp DE, Virginia Retirement Systems ET AL, Vanguard Group Inc., Perkins Capital Management Inc. and Icon Advisers Inc. Co.. View Insider Buying and Selling for ANI Pharmaceuticals.

How do I buy ANI Pharmaceuticals stock?

Shares of ANI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ANI Pharmaceuticals stock cost?

One share of ANI Pharmaceuticals stock can currently be purchased for approximately $45.97.

Analyst Ratings

Consensus Ratings for ANI Pharmaceuticals (NASDAQ:ANIP) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $68.00 (47.92% upside)

Analysts' Ratings History for ANI Pharmaceuticals (NASDAQ:ANIP)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/6/2017Roth CapitalSet Price TargetHold$56.00LowView Rating Details
4/6/2017GuggenheimReiterated RatingBuy$80.00HighView Rating Details
8/5/2016Oppenheimer Holdings Inc.Boost Price TargetOutperform$65.00 -> $71.00N/AView Rating Details
7/19/2016Citigroup IncUpgradeOutperform$65.00N/AView Rating Details
6/22/2016Raymond James Financial, Inc.Initiated CoverageStrong-Buy$68.00N/AView Rating Details
5/24/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for ANI Pharmaceuticals (NASDAQ:ANIP)
Earnings by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)
Earnings History by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017$0.70$0.74$39.63 million$36.60 millionViewListenView Earnings Details
3/2/2017Q4 2016$1.09$0.84$40.98 million$38.20 millionViewListenView Earnings Details
11/3/2016Q316$1.08$1.09$34.34 million$38.53 millionViewN/AView Earnings Details
8/4/2016Q216$0.77$1.11$27.63 million$31.30 millionViewN/AView Earnings Details
5/5/2016Q116$0.64$0.76$21.03 million$20.60 millionViewN/AView Earnings Details
2/23/2016Q415$0.60$0.52$18.13 million$18.04 millionViewN/AView Earnings Details
11/3/2015Q315$0.63$0.80$21.37 million$20.00 millionViewN/AView Earnings Details
8/4/2015Q215$0.54$0.31$20.30 million$19.52 millionViewN/AView Earnings Details
5/5/2015Q115$0.56$0.53$19.86 million$18.80 millionViewN/AView Earnings Details
2/19/2015Q414$0.57$0.60$17.98 million$21.04 millionViewN/AView Earnings Details
11/3/2014Q314$0.43$0.59$14.60 million$17.40 millionViewN/AView Earnings Details
8/4/2014Q214($0.01)($0.21)$7.95 million$6.60 millionViewN/AView Earnings Details
5/5/2014Q115$0.32$0.33$11.40 million$10.90 millionViewN/AView Earnings Details
2/27/2014Q414$0.35$5.32 million$10.53 millionViewN/AView Earnings Details
11/7/2013$0.16ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ANI Pharmaceuticals (NASDAQ:ANIP)
Current Year EPS Consensus Estimate: $3.84 EPS
Next Year EPS Consensus Estimate: $4.61 EPS


Dividend History for ANI Pharmaceuticals (NASDAQ:ANIP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ANI Pharmaceuticals (NASDAQ:ANIP)
Insider Ownership Percentage: 31.60%
Institutional Ownership Percentage: 51.56%
Insider Trades by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)
Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)
Insider Trades by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2016Arthur PrzybylInsiderSell37,455$66.97$2,508,361.35View SEC Filing  
8/8/2016Robert W SchrepferVPSell12,500$67.06$838,250.00View SEC Filing  
12/18/2015James G MarkenVPSell3,500$43.26$151,410.00View SEC Filing  
11/12/2015Arthur PrzybylCEOBuy2,500$40.95$102,375.00View SEC Filing  
3/19/2015James G MarkenVPSell15,000$66.50$997,500.00View SEC Filing  
9/15/2014Ross J ManganoDirectorBuy3,000$27.49$82,470.00View SEC Filing  
9/9/2014Arthur PrzybylCEOBuy1,000$26.50$26,500.00View SEC Filing  
6/18/2014James G MarkenVPSell5,000$34.28$171,400.00View SEC Filing  
5/8/2014Tracy MarshbanksDirectorSell1,381$30.02$41,457.62View SEC Filing  
5/7/2014Ross ManganoDirectorBuy2,000$30.38$60,760.00View SEC Filing  
3/21/2014Tracy MarshbanksDirectorSell21,767$31.42$683,919.14View SEC Filing  
3/20/2014Meridian Venture Partners Ii Lmajor shareholderSell20,922$32.12$672,014.64View SEC Filing  
3/19/2014Tracy MarshbanksDirectorSell25,358$33.68$854,057.44View SEC Filing  
3/18/2014Meridian Venture Partners Ii Lmajor shareholderSell60,540$34.07$2,062,597.80View SEC Filing  
3/13/2014Meridian Venture Partners Ii Lmajor shareholderSell87,723$32.48$2,849,243.04View SEC Filing  
11/7/2013Ross J ManganoDirectorBuy9,000$11.27$101,430.00View SEC Filing  
8/20/2013Ross J ManganoDirectorBuy10,000$7.47$74,700.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ANI Pharmaceuticals (NASDAQ:ANIP)
Latest Headlines for ANI Pharmaceuticals (NASDAQ:ANIP)
DateHeadline logoANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ANIP-US : May 15, 2017 - May 15 at 3:32 PM logoANI Pharmaceuticals Inc (ANIP) Given Average Recommendation of "Buy" by Analysts - May 12 at 11:20 AM logoANI Pharmaceuticals Inc (ANIP) Stock Rating Lowered by Zacks Investment Research - May 10 at 5:22 PM logoANI Pharmaceuticals Announces Launch of Pindolol Tablets - May 8 at 10:59 AM logoANI Pharmaceuticals Inc (ANIP) Short Interest Up 10.0% in April - May 8 at 8:52 AM logo Analysts Expect ANI Pharmaceuticals Inc (ANIP) Will Announce Quarterly Sales of $46.2 Million - May 7 at 9:22 AM logoANI Pharmaceuticals Q1 Profit Down, Reaffirms FY17 View - May 6 at 1:40 AM logoBRIEF-Ani Pharmaceuticals reports Q1 GAAP earnings per share $0.10 - May 6 at 1:40 AM logo10-Q: ANI PHARMACEUTICALS INC - May 6 at 1:40 AM logoInvestor Network: ANI Pharmaceuticals, Inc. to Host Earnings Call - May 6 at 1:40 AM logoANI Pharmaceuticals Reports First Quarter Results and Year-To-Date 2017 Highlights and Reaffirms Guidance - May 6 at 1:40 AM logoANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ANIP-US : May 4, 2017 - May 6 at 1:40 AM logoEdited Transcript of ANIP earnings conference call or presentation 4-May-17 2:30pm GMT - May 5 at 8:40 PM logoANI Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ANIP) : May 5, 2017 - May 5 at 8:40 PM logoANI Pharmaceuticals Inc (ANIP) Expected to Announce Earnings of $0.70 Per Share - May 5 at 8:52 AM logoETFs with exposure to ANI Pharmaceuticals, Inc. : May 4, 2017 - May 4 at 8:38 PM logoANI Pharmaceuticals Inc (ANIP) Announces Earnings Results - May 4 at 4:43 PM logoANI Pharmaceuticals Inc (ANIP) Releases FY17 Earnings Guidance - May 4 at 9:41 AM logoANI posts 1Q profit - May 4 at 9:12 AM logoANI Pharmaceuticals (ANIP) Getting Favorable Media Coverage, Study Finds - May 4 at 7:58 AM logoANI Pharmaceuticals Inc (ANIP) Upgraded to "Hold" at Zacks Investment Research - May 3 at 6:36 PM logoANI Pharmaceuticals Inc (ANIP) to Release Earnings on Wednesday - May 1 at 9:18 AM logoANI Pharmaceuticals (ANIP) Earning Positive News Coverage, Report Finds - April 30 at 12:27 PM logoANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2017 Financial Results - April 27 at 3:56 PM logoFavorable Media Coverage Somewhat Likely to Impact ANI Pharmaceuticals (ANIP) Stock Price - April 27 at 2:42 PM logoANI Pharmaceuticals (ANIP) Receiving Favorable Press Coverage, Report Finds - April 24 at 5:16 PM logoANI Pharma (ANIP) Launches Indapamide Tablets - - April 21 at 3:35 PM logoETFs with exposure to ANI Pharmaceuticals, Inc. : April 21, 2017 - April 21 at 3:35 PM logoANI Pharmaceuticals Announces Launch of Indapamide Tablets - April 19 at 3:31 PM logoANI Pharmaceuticals Inc (ANIP) Given Consensus Recommendation of "Buy" by Brokerages - April 17 at 12:42 PM logoPositive Media Coverage Very Unlikely to Impact ANI Pharmaceuticals (ANIP) Stock Price - April 14 at 4:36 PM logo$0.70 Earnings Per Share Expected for ANI Pharmaceuticals Inc (ANIP) This Quarter - April 14 at 10:42 AM logoETFs with exposure to ANI Pharmaceuticals, Inc. : April 7, 2017 - April 7 at 8:36 PM logoGuggenheim Reaffirms Buy Rating for ANI Pharmaceuticals Inc (ANIP) - April 6 at 2:13 PM logoANI Pharmaceuticals Inc (ANIP) Downgraded by TheStreet to "C" - April 5 at 5:34 PM logoANI Pharmaceuticals: Coming Back From Oversold Levels - Seeking Alpha - March 28 at 3:31 PM logoANI Pharmaceuticals Inc (ANIP) Receives Consensus Rating of "Buy" from Brokerages - March 21 at 1:39 PM logoANI PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - March 14 at 3:28 PM logoMoving Average Crossover Alert: ANI Pharmaceuticals (ANIP) - Nasdaq - March 13 at 3:37 PM logoMoving Average Crossover Alert: ANI Pharmaceuticals (ANIP) - March 13 at 7:53 AM logoANI Pharmaceuticals Revs The Throttle Of Corticotropin Candidate - Seeking Alpha - March 9 at 3:18 PM logoANI PHARMACEUTICALS INC Financials - March 8 at 3:38 PM logo10-K: ANI PHARMACEUTICALS INC - March 2 at 8:48 PM logoBRIEF-ANI Pharmaceuticals reports Q4 loss per share $0.09 - March 2 at 8:48 PM logoQ4 2016 ANI Pharmaceuticals Inc Earnings Release - Before Market Open - March 2 at 8:48 PM logoANI Pharmaceuticals Reports Full Year 2016 Results and Fourth Quarter Results and Provides 2017 Guidance - March 2 at 8:48 PM logoANI PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E - March 2 at 8:48 PM logoANI Pharmaceuticals, Inc. Bottom Line Rises 63% In Q4 - Nasdaq - March 2 at 3:47 PM
News IconBRIEF-Ani Pharma acquires Inderal XL and Innopran XL - February 25 at 8:29 PM logoANI Pharma acquires two hypotension meds - Seeking Alpha - February 24 at 8:44 PM



ANI Pharmaceuticals (ANIP) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff